FFilingSight

Biogen Inc. (BIIB) 10-K Red Flags

Risk signals extracted deterministically from Biogen Inc.’s SEC 10-K/10-Q XBRL filings — no LLM, every finding cites the underlying data.

Detected red flags (14)

  • Going concern doubt: The term "going concern" appears in 4 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
  • Material weakness in internal controls: The term "material weakness" appears in 19 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
  • Operating cash flow exceeds net income: OCF is 1.33x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
  • Gross margin expansion: Gross margin expanded +3.0%pp (from 26.4% to 29.4%), indicating improved pricing power, cost efficiency, or favorable product mix.
  • Endogenous analysis: 2 positive signal(s) versus 2 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
  • 3 new XBRL disclosure(s) in latest filing — expanding reporting scope.
  • 20 disclosure(s) dropped from prior year — reduced reporting granularity.
  • Ongoing high-severity risk language: Going concern doubt, Material weakness in internal controls.
  • Revenue declined **+3.3%** YoY to $9.84B.
  • 5-year revenue CAGR **-7.3%**; 10y CAGR +0.2%.
  • Market cap $31.91B at $216.12 per share.
  • Trailing P/E 27.12, P/S 3.24, P/B 2.16.
  • Going concern doubt: The term "going concern" appears in 4 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
  • Material weakness in internal controls: The term "material weakness" appears in 19 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.

Filings & ownership

  • Latest annual report (10-K) filed Feb 6, 2026.
  • Latest quarterly report (10-Q) filed Apr 29, 2026.
  • 17 recent 8-K material-event filings in the index.
  • Recent insider Form 4s: 0 buy vs 0 sell transactions.
  • ~10,000+ recent 13F-HR filings reference Biogen Inc.; broad institutional reporting.
  • Recent filers include Woodford Investment Management Ltd, Woodford Investment Management Ltd, Woodford Investment Management Ltd.
  • 3 recent 13D activist/beneficial-ownership filings — potential catalyst.
  • 17 recent 13G passive institutional ownership notices.

Full BIIB analyst report

Valuation (DCF & Graham), technicals, macro exposure, risk scorecard and 13F/13D ownership.

View full report →

Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.